Pharmaceuticals business segment growth likely to be healthy Recent long term contracts in the radiopharma business as well as approval for Rubyfill in the US are expected to strengthen the speciality sub-segment growth, which is likely to grow at 12.3% CAGR in FY19-21E to | 3572 crore on the back of strong growth in the radiopharma business and consolidation of pharmacy business. CDMO business is witnessing strong traction on the back of robust order book and incremental realisation in API segment. The generic business is also registering decent growth on the back of base...